Clinical trials
Immune Checkpoint Inhibitor clinical trials
Below are recruiting immune checkpoint inhibitor clinical trials, each written for real people, not researchers. We’re tracking 179 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07775820Recruiting
Retrying immunotherapy after lung inflammation
This trial looks at whether people with lung cancer who had lung inflammation from immunotherapy can safely try immunotherapy again. It aims to see if restarting treatment helps without causing severe side effects.
Guangzhou, GuangdongAges 18 years+ - NCT06408688RecruitingPhase 4
Mistletoe extract added to immunotherapy for advanced solid tumors
This trial tests whether adding mistletoe extract (Iscador) to standard immunotherapy can make the treatment safer and boost the immune system's response against advanced solid tumors (excluding skin cancer). If you are already receiving or about to start a checkpoint inhibitor, this study may help understand if the combination works better.
BadenAges 18 years+ - NCT06470997Recruiting
Biomarkers for hepatitis from immunotherapy
This study looks for certain markers in the blood that can help diagnose liver inflammation caused by immunotherapy. It aims to better understand this side effect and how to treat it.
Montpellier, FranceAges 18 years+ - NCT07453342Recruiting
Safety of immunotherapy side effects and restarting treatment
This study looks at patients who had side effects from cancer immunotherapy (checkpoint inhibitors). The goal is to understand those side effects and whether it is safe to restart immunotherapy after they resolve.
Beijing, Beijing MunicipalityAges 18 years+ - NCT06819735RecruitingPhase 1/Phase 2
Testing DT-7012 in Advanced Solid Tumors
This trial tests a new drug called DT-7012, given alone or with another immunotherapy, in people with advanced solid tumors that have stopped responding to standard treatments. The goal is to see if DT-7012 can shrink tumors or slow their growth.
Scottsdale, ArizonaAges 18 years+ - NCT05813418Recruiting
Finding blood and other clues for immune side effects
This study looks for early “predictive clues” (often blood or test markers) that can forecast immune-related side effects in people treated with immune checkpoint medicines. The goal is to help doctors recognize who may be more likely to have these side effects while receiving treatment.
Amiens, PicardieAges 18 years+ - NCT06715982RecruitingPhase 2
JAK inhibitor for severe skin rash from immunotherapy
This study tests a JAK inhibitor pill for people with severe skin rashes caused by immunotherapy drugs like Keytruda or Opdivo. It aims to help control the rash and allow you to keep benefiting from your cancer treatment.
Quzhou, ZhejiangAges 18–80 - NCT06154538RecruitingPhase 2
Immunotherapy plus chemo vs. chemo alone for advanced colorectal cancer before surgery
This trial tests whether adding immunotherapy (a treatment that helps your immune system fight cancer) to standard chemotherapy before surgery works better than chemotherapy alone for people with locally advanced colorectal cancer.
Beijing, Beijing MunicipalityAges 18–75 - NCT07748325RecruitingPhase 2
Checking if immunotherapy after surgery helps prevent lung cancer return
This trial is for people with non-small cell lung cancer who have already had immunotherapy and chemotherapy before surgery, followed by complete removal of the tumor. It tests whether continuing immunotherapy after surgery (adjuvant treatment) can lower the risk of cancer coming back compared to just watching and waiting.
Chengdu, SichuanAges 18–75 - NCT06745908RecruitingPhase 3
New drug combo for lung cancer after immunotherapy stops working
This trial tests a new drug combination (N-803 and tislelizumab with chemotherapy) for people whose lung cancer stopped responding to standard immunotherapy. The goal is to see if this treatment can help shrink tumors or slow the cancer's growth.
Springdale, ArkansasAges 18–90 - NCT04322617RecruitingPhase 2/Phase 3
Anlotinib plus immunotherapy for lung cancer after first treatment
This trial studies an oral targeted medicine (anlotinib) combined with an immunotherapy (checkpoint inhibitor) for lung cancer that did not respond to first-line chemo-immunotherapy. It may help shrink tumors and improve disease control after standard treatment has failed.
Changsha, HunanAges 18 years+ - NCT04807114Recruiting
Blood or tissue testing to find markers for lung cancer treatment
This study uses detailed “single-cell” testing to look for markers that can predict how well immunotherapy works and what side effects may happen. It is for people with non-small cell lung cancer starting standard first-line treatment.
LeuvenAges 18–120 - NCT05037825Recruiting
Study gut microbes with immune therapy in several solid cancers
This trial looks at how the gut microbiome (the bacteria in your digestive system) relates to outcomes when you take standard immune “checkpoint” cancer medicines. If you’re eligible, they’ll collect stool samples while you receive treatment for certain cancers.
Elizabethtown, KentuckyAges 18 years+ - NCT05059951Recruiting
Chemotherapy With or Without Immunotherapy for Lung Cancer
This trial looks at whether adding an immunotherapy drug (an immune checkpoint inhibitor) to chemotherapy helps people with lung cancer live better or respond better. You might be considered if your cancer is confirmed, you can tolerate treatment, and imaging shows measurable spots.
Changsha, HunanAges 18 years+ - NCT05726396RecruitingPhase 2
Microbiome therapy for steroid-resistant immune colitis
This Phase 2 pilot study tests a “restorative microbiota therapy” (RMT) to treat colitis caused by immune checkpoint inhibitors when standard treatments like steroids are not working. It aims to see if this approach is safe and practical, and may improve diarrhea and gut inflammation.
Brainerd, MinnesotaAges 18 years+ - NCT05799898Recruiting
Fast heart and vessel check for people on immune cancer drugs
This trial looks at a faster heart and blood-vessel assessment for people who are taking immune cancer drugs and have been referred because they might be having a heart-related side effect. It may help by speeding up evaluation and treatment decisions when symptoms raise concern.
ParisAges 18 years+ - NCT05878977Recruiting
Testing biomarkers in immunotherapy for advanced melanoma
This trial looks at tissue and scan-related markers (“biomarkers”) to better understand how immunotherapy works in people with advanced melanoma. You may receive standard first-line immunotherapy, and your recent scans and health details will help researchers study why some people respond better than others.
LjubljanaAges 18 years+ - NCT05941741RecruitingPhase 3
Tested low-dose radiation plus cadonilimab for nasopharyngeal cancer
This Phase 3 trial studies whether adding low-dose radiation to cadonilimab (an immune therapy) can improve outcomes for people newly diagnosed with a specific type and stage of nasopharyngeal cancer. If you’re eligible, it may offer a new treatment approach and helps researchers confirm whether it works best.
Guangzhou, GuangdongAges 18–70 - NCT06132984Recruiting
Heart MRI monitoring for immunotherapy-related heart issues
This study uses heart MRIs to monitor women with gynecologic cancers who are about to start immunotherapy. The goal is to detect early signs of heart problems so doctors can take action quickly.
Chengdu, SichuanAges 18–75 - NCT06197581Recruiting
Safety of Radiation with Modern Breast Cancer Drugs
This study checks if giving certain modern breast cancer drugs at the same time as radiation is safe. It's for women who need radiation and are also taking one of these drugs: capecitabine, a CDK4/6 inhibitor, a PARP inhibitor, immunotherapy, or a HER2 inhibitor.
Beijing, Beijing MunicipalityAges 18–70 - NCT06259162Recruiting
LAG3 study in triple-negative breast cancer
This trial is studying a protein called LAG3 in triple-negative breast cancer. It is for people who will receive chemotherapy before surgery to see if LAG3 levels affect how well the treatment works.
SeoulAges Any age - NCT06398418RecruitingPhase 1
Study of R-5780 with PD-1 drugs for advanced solid tumors
This trial tests a new drug called R-5780 combined with standard immunotherapy (PD-1 checkpoint inhibitors) for people with advanced skin cancers or other solid tumors that have stopped responding to treatment. The goal is to see if this combination is safe and helps fight the cancer.
Nashville, TennesseeAges 18–80 - NCT06463665RecruitingPhase 2
Virus therapy with chemo and immunotherapy for advanced lung cancer
This trial tests a new treatment that uses a virus to attack cancer cells, combined with standard chemotherapy and an immunotherapy drug, for people with advanced non-small cell lung cancer that has gotten worse after initial treatment. The goal is to see if this combination works better than a different chemotherapy drug alone.
Bullhead City, ArizonaAges 18 years+ - NCT06558773RecruitingPhase 2
New drug combo for previously treated colorectal cancer
This trial tests a combination of a GSL synthesis inhibitor, an immunotherapy drug, and/or regorafenib in people with a specific type of colorectal cancer (pMMR/MSS) that has not responded to at least two prior treatments. The goal is to see if this new approach can help shrink or control the cancer.
Beijing, Biotherapeutic Department of Chinsese PLA Gereral HospitalAges 18–75
Hear when a new Immune Checkpoint Inhibitor trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for immune checkpoint inhibitor?
- Yes. Clin2 currently lists 179 recruiting immune checkpoint inhibitor studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a immune checkpoint inhibitor trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a immune checkpoint inhibitor trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.